Story perspectives

Bloomsbury's Gene Therapy Advances Hope for Rare Diseases

5/7/2025

40 4

Summary

Story summary

Bloomsbury Genetic Therapies has made significant strides in the fight against rare diseases, earning orphan drug designation from the U.S. FDA for its groundbreaking gene therapy, BGT-OTCD, aimed at treating ornithine transcarbamylase deficiency. With the phase 1/2 HORACE trial kicking off in November 2023, hope is on the horizon for patients. Additionally, the company has gained rare pediatric disease designations for BGT-NPC and BGT-DTDS, furthering its commitment to innovative treatments.

1 of 1

Story summary

Bloomsbury Genetic Therapies has made significant strides in the fight against rare diseases, earning orphan drug designation from the U.S. FDA for its groundbreaking gene therapy, BGT-OTCD, aimed at treating ornithine transcarbamylase deficiency. With the phase 1/2 HORACE trial kicking off in November 2023, hope is on the horizon for patients. Additionally, the company has gained rare pediatric disease designations for BGT-NPC and BGT-DTDS, furthering its commitment to innovative treatments.